Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs892119
rs892119
0.010 GeneticVariation BEFREE (2) In Cox regression analyses, three SNPs (PIK3R1 rs1862162, AKT2 rs892119, and PIK3CA rs2699887) showed significant associations with survival of endometrial cancer patients. 22146979

2012

dbSNP: rs2699887
rs2699887
0.010 GeneticVariation BEFREE (2) In Cox regression analyses, three SNPs (PIK3R1 rs1862162, AKT2 rs892119, and PIK3CA rs2699887) showed significant associations with survival of endometrial cancer patients. 22146979

2012

dbSNP: rs7312175
rs7312175
0.010 GeneticVariation BEFREE (3) KRAS rs7312175 and PIK3CA rs6443624 had significant effects on recurrence of endometrial cancer individually and combined in a locus-dosage manner (adjusted P (trend) = 0.003). 22146979

2012

dbSNP: rs6443624
rs6443624
0.010 GeneticVariation BEFREE (3) KRAS rs7312175 and PIK3CA rs6443624</span> had significant effects on recurrence of endometrial cancer individually and combined in a locus-dosage manner (adjusted P (trend) = 0.003). 22146979

2012

dbSNP: rs4430796
rs4430796
0.030 GeneticVariation BEFREE rs4430796 polymorphism of HNF1B gene influences independently the prognosis of EC patients with a potential effect on tumor chemo-sensitivity. 25885815

2015

dbSNP: rs3184504
rs3184504
0.010 GeneticVariation BEFREE A combined analysis revealed one genome-wide significant polymorphism, rs3184504, on chromosome 12q24 (OR = 1.10, P = 7.23 × 10(-9)) with shared effects on CRC and EC risk. 26621817

2015

dbSNP: rs3768235
rs3768235
0.010 GeneticVariation BEFREE A polymorphism in exon 3 (638G-->A) was seen in 4/42 (9.5%) MSI-positive endometrial cancers and 0/5 MSI-positive endometrial cancer cell lines. 11180594

2001

dbSNP: rs1799814
rs1799814
0.020 GeneticVariation BEFREE Accordingly, Thr461Asn status was not significantly associated with endometrial cancer risk. 21270613

2011

dbSNP: rs4775936
rs4775936
0.010 GeneticVariation BEFREE Adjusting for endometrial cancer risk factors, the A allele of rs4775936 in CYP19 was significantly associated (OR(per allele)=1.22, 95% CI=1.01-1.47, p(trend)=0.04), while the T allele of rs10046 was marginally associated with increased risk of endometrial cancer (OR(per allele)=1.20, 95% CI=0.99-1.45, p(trend)=0.06). 22633539

2012

dbSNP: rs10046
rs10046
0.010 GeneticVariation BEFREE Adjusting for endometrial cancer risk factors, the A allele of rs4775936 in CYP19 was significantly associated (OR(per allele)=1.22, 95% CI=1.01-1.47, p(trend)=0.04), while the T allele of rs10046 was marginally associated with increased risk of endometrial cancer (OR(per allele)=1.20, 95% CI=0.99-1.45, p(trend)=0.06). 22633539

2012

dbSNP: rs1256049
rs1256049
0.010 GeneticVariation BEFREE After adjusting for potential confounders, we observed no association between ESR2 gene polymorphisms and endometrial cancer risk [rs1256049 (OR = 1.2; 95%CI: 0.7-2.3), rs1271572 (OR = 0.8; 95%CI: 0.5-1.1) and CA repeat (22 repeat allele versus > or = 22 repeat allele, OR = 1.1; 95%CI: 0.7-1.7)]. 15280642

2004

dbSNP: rs1271572
rs1271572
0.010 GeneticVariation BEFREE After adjusting for potential confounders, we observed no association between ESR2 gene polymorphisms and endometrial cancer risk [rs1256049 (OR = 1.2; 95%CI: 0.7-2.3), rs1271572 (OR = 0.8; 95%CI: 0.5-1.1) and CA repeat (22 repeat allele versus > or = 22 repeat allele, OR = 1.1; 95%CI: 0.7-1.7)]. 15280642

2004

dbSNP: rs4680
rs4680
0.040 GeneticVariation BEFREE Although no obvious associations were detected between COMT Val158Met and endometrial cancer susceptibility in the pooled analysis, we noted significantly decreased endometrial cancer risk for Val/Met versus Val/Val, and Met/Met + Val/Met versus Val/Val genetic models in the postmenopausal female (OR = 0.795, 95%CI = 0.656-0.962, P = 0.019; and OR = 0.819, 95%CI = 0.683-0.983, P = 0.032; respectively), and similar results existed in high-quality studies (OR = 0.835, 95%CI = 0.726-0.961, P = 0.012; and OR = 0.853, 95%CI = 0.747-0.974, P = 0.019; respectively). 24390993

2013

dbSNP: rs1057520001
rs1057520001
0.010 GeneticVariation BEFREE An association between endometrial cancer and the polymorphism at codon 31 (AGC/serine to AGA/arginine [Ser(31)Arg]) of the p21 gene, which is known to be a downstream mediator of p53, has also been reported. 15099969

2004

dbSNP: rs886039484
rs886039484
0.010 GeneticVariation BEFREE An association between endometrial cancer and the polymorphism at codon 31 (AGC/serine to AGA/arginine [Ser(31)Arg]) of the p21 gene, which is known to be a downstream mediator of p53, has also been reported. 15099969

2004

dbSNP: rs10012
rs10012
0.030 GeneticVariation BEFREE An association of CYP1B1 gene R48G polymorphism with endometrial cancer was found [GG vs. GC+CC: odds ratio (OR)=0.55, 95% confidence interval (CI): 0.42-0.73, P<0.0001; GG vs. CC: OR=0.46, 95% CI: 0.23-0.91, P=0.03]. 21191305

2011

dbSNP: rs1870050
rs1870050
0.020 GeneticVariation BEFREE An inverse association was found between endometrial cancer and single nucleotide polymorphism rs1870050 in the promoter region with ORs of 0.81 (95% CI, 0.68-0.97) and 0.58 (95% CI, 0.42-0.80) for the AC and CC genotypes, respectively. 17507620

2007

dbSNP: rs12970291
rs12970291
0.010 GeneticVariation BEFREE Another polymorphism, rs12970291 near gene TSHZ1, was associated with both CRC and EC (OR = 1.26, P = 4.82 × 10(-8)), with the alleles showing opposite effects on the risks of the two cancers. 26621817

2015

dbSNP: rs6259
rs6259
0.020 GeneticVariation BEFREE Association of endometrial cancer risk with a functional polymorphism (Asp(327)Asn) in the sex hormone-binding globulin gene. 17315164

2007

dbSNP: rs1042522
rs1042522
0.080 GeneticVariation BEFREE Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. 23624782

2013

dbSNP: rs1131691014
rs1131691014
0.080 GeneticVariation BEFREE Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. 23624782

2013

dbSNP: rs878854066
rs878854066
0.080 GeneticVariation BEFREE Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. 23624782

2013

dbSNP: rs1353702185
rs1353702185
0.020 GeneticVariation BEFREE Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. 23624782

2013

dbSNP: rs757511141
rs757511141
0.010 GeneticVariation BEFREE Association of MDM2 SNP309 and TP53 Arg72Pro polymorphisms with risk of endometrial cancer. 23624782

2013

dbSNP: rs1042522
rs1042522
0.080 GeneticVariation BEFREE Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53 Arg72Pro polymorphism with the risk of endometrial cancer in Japanese subjects. 15723718

2005